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Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine tumor of the skin.  Originally described by 
Toker in 1972, the exact origin of Merkel cells is still a matter of debate, with some hypothesizing an origin from 
neural crest stem-cells.  At presentation, 66% of patients have local disease, 27% have nodal involvement, and 7% 
have distant metastases.  The reported incidence has more than tripled over the last 20 years, with some authors 
contributing this increase to improved detection by the immunohistochemical marker cytokeratin-20 (CK20).  Known 
risk factors include T-cell suppression and extensive prior sun exposure.  This link to immune suppression led to the 
discovery of the Merkel cell polyomavirus (MCPyV) in 2008.
Current thought, through several experimental observations, suggests that tumor growth is dependent on 
contribution of the MCPyV and independent immune system involvement.  MCPyV is incorporated into host DNA 
causing an integration mutation.  A truncation mutation follows, eliminating viral replication, and allows persistent 
oncogenic function.  Persistent viral antigen expression inactivates the retinoblastoma tumor suppressor protein 
allowing tumor growth.  Independently, MCPyV evades the immune system by UV-mediated immune tolerance, 
chronic antigen exposure, downregulation of antigen expression, and immunosuppressive cytokines.   The other 
critical tumor suppressor pathway that is altered in the course of tumor progression is p53.  It is also believed that 
the MCPyV can inactivate the AKT-mTOR signaling pathway, thus promoting tumor growth.
Immune response is currently being studied as a prognostic indicator. The presence of MCPyV antibodies appears to 
correlate with tumor burden in MCC patients.  High antibody titers, (>10,000), appears to result in better progression-
free survival than low titers.  High intratumoral infiltration of CD8+ cells may confer increased survival, compared 
to sparse or no infiltration.  In the future, vaccination against MCPyV, or modification and enhancement of the host 
immune response, offers a promising role in the treatment of MCC.
Currently, there are no consensus guidelines for staging.  (18)F-fluorodeoxyglucose positron emission tomography in 
conjunction with high resolution CT scan appears to offer the most accurate staging of disease.  Surgery remains the 
mainstay of treatment with either wide local excision or treatment with Mohs surgery to ensure complete removal.  
Patients who are able to undergo sentinel lymph node biopsy are encouraged to do so.  Radiation and chemotherapy 
may be used as adjuvant therapy.   
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Patient: H.K. is a 97 year-old Caucasian female.
History of Present Illness: Patient presented from a personal care facility with a one month history of a 
rapidly enlarging and fungating mass on the left cheek.  Excisional biopsy was performed and a diagnosis of Merkel 
cell carcinoma was established.  After extensive family counseling, wide local excision was agreed upon as a course 
of action.  On the day of the proposed surgery (within one month of the initial diagnosis) the lesion had recurred 
to the original size. On physical exam she was found to have pre-auricular, sub-mental, and anterior cervical 
lymphadenopathy. She also had a mild wound infection at the biopsy site. With the patient in poor health, and the 
possibility of local metastatic disease, the family elected hospice care.     
Medical History: Dementia, dysphagia, hypothyroidism, congestive heart failure, type II diabetes, chronic kidney 
disease, chronic obstructive pulmonary disease
Family History: Unknown
Current Medications: Lorazepam, levothyroxine, fentanyl, acetaminophen, cephalexin/doxycycline (for wound 
infection)
Physical Examination: 2.3 x 1.5 x 1.2 cm hemorrhagic crusted exophytic tumor on the left cheek.
Biopsy: CBL Path (D12NY1-0414557, 12/28/2012) Left cheek: “Ulcerated dense multinodular dermal/subcuticular 
infiltrate of large poorly differentiated basaloid epithelial cells with ‘salt and pepper’ chromatin and high n:c ratios.  
Abundant mitotic activity is present. With immunostains, the lesional cells stain in a characteristic fashion with CK20, 
CK7 (rare), neurofilament, chromogranin, and synaptophysin (patchy and mild), and do not stain with TTF-1, LCA, or 
S100.”   
Reason for Presentation: Interest
Figure 1A: December 
2012:  Hemorrhagic crusted 
exophytic tumor on the left 
cheek.
Figure 2A: H&E 
December 2012: Infiltrating 
dermal nodule.
Figure 2D: H&E December 
2012: Vascular invasion of 
tumor cells.
Figure 1B: January 2013: 
Four weeks s/p excisional 
biopsy showing recurrence.
Figure 2B: H&E December 
2012: Infiltrating cords of 
basaloid cells.
Figure 2C: H&E December 
2012: Sheets of small 
basophilic cells in the dermis 
with vesicular nuclei.
Figure 2E: December 
2012: Positive perinuclear dot 
CK20 staining.
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Figure 2F: December 
2012: Chromogranin positive 
cells.
